<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997412</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080ATW07T</org_study_id>
    <nct_id>NCT00997412</nct_id>
  </id_info>
  <brief_title>Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis</brief_title>
  <acronym>Myfortic</acronym>
  <official_title>Randomized, Double-blind, Double-dummy Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qualitix Clinical Research Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qualitix Clinical Research Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an randomized, double-blind, double-dummy trial, and the objective is to compare the&#xD;
      efficacy and safety of Mycophenolic acid (MA) and Azathioprine (AZA), immunosuppressive&#xD;
      drugs, in myasthenia gravis patients. This prospective study will enroll 40 myasthenia gravis&#xD;
      (MG) patients who are poor controlled under prior steroid therapy. All subjects should be&#xD;
      randomly assigned to MA group and AZA group that will receive routine pyridostigmine and&#xD;
      prednisolone in combination with MA or AZA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double-dummy study to keep the blinded quality.&#xD;
&#xD;
        -  MA group: 1 tablet AZA placebo and 4 tables MA (180 mg/tab,720 mg/day) twice daily.&#xD;
&#xD;
        -  AZA group: 1 tablet AZA (50mg/tab) and 4 tables MA placebo twice daily.&#xD;
&#xD;
             -  When patients achieve minimal manifestation (MM, i.e. complete remission), which&#xD;
                lead to normal daily routine, the dose of pyridostigmine should reduce to 240&#xD;
                mg/day (4 tablets) or less. The dose of steroid should be stepped down by 10 mg qod&#xD;
                (every other day) for every 2 weeks until the dose achieves 40 mg qod. After that,&#xD;
                the dose should be stepped down by 5 mg qod for every month.&#xD;
&#xD;
             -  When disease progresses and is no longer maintaining minimal manifestation, the&#xD;
                dose of steroid will be stepped up by 10 mg qod for every 2 weeks until achieve&#xD;
                clinical stable remission. The taper rule of steroid could start again 1 month&#xD;
                after stabilization.&#xD;
&#xD;
             -  Every patient will be treated for 1 year. If the patient could not achieve MM&#xD;
                within 1 year, the blind of individual patient will be opened and the patients will&#xD;
                be crossed over to another medical treatment. The efficacy and safety of second&#xD;
                medication will be observed openly until the end of study.&#xD;
&#xD;
             -  When the muscle weakness worsens under established study schedule, plasmapheresis&#xD;
                could be conducted to improve the condition rapidly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of two arms patients achieve minimal manifestation (MM, i.e. complete remission)</measure>
    <time_frame>One year after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osserman clinical classification</measure>
    <time_frame>One year after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myasthenia gravis (MG) score</measure>
    <time_frame>One year after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid</intervention_name>
    <description>180 mg/tablet, 4 tablets twice daily</description>
    <arm_group_label>MA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZA</intervention_name>
    <description>1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily</description>
    <arm_group_label>AZA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female age between 20-70 (including 20 and 70 years old).&#xD;
&#xD;
          -  Osserman II and III Myasthenia Gravis.&#xD;
&#xD;
          -  Positive serum anti-acetylcholine receptor antibodies.&#xD;
&#xD;
          -  Poor control of disease with daily dose of prednisone â‰¥ 30 mg or 0.5 mg/kg at 3 months&#xD;
             before enrollment.&#xD;
&#xD;
          -  Without immunosuppressive therapy other than steroid.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular MG or minimal clinical syndrome that would not require the therapy of steroids.&#xD;
&#xD;
          -  Negative serum anti-acetylcholine receptor antibodies.&#xD;
&#xD;
          -  Use immunosuppressants other than steroids in the preceding year.&#xD;
&#xD;
          -  Previous use other investigational medication within 3 months or current participate&#xD;
             other clinical study.&#xD;
&#xD;
          -  Poor renal function: serum creatinine &gt; 3.0 mg/dl or estimated creatinine clearance &lt;&#xD;
             30 ml/min&#xD;
&#xD;
          -  Females who are pregnancy or breast-feeding.&#xD;
&#xD;
          -  Recent history, within 5 years, of malignancy&#xD;
&#xD;
          -  Unwilling or unable to participate the necessary continuous visits and examinations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiann-Horng Yeh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shin Kong Wu Ho-Su Memorial Hospital</affiliation>
  </overall_official>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>October 16, 2009</last_update_submitted>
  <last_update_submitted_qc>October 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jiann-Horng Yeh / M.D.</name_title>
    <organization>Shin Kong Wu Ho-Su Memorial Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

